Fatal breast cancer risk in relation to use of unopposed estrogen and combined hormone therapy
- 242 Downloads
Use of combined hormone therapy (CHT) is associated with increased breast cancer incidence, but it is unclear whether this translates into increased breast cancer mortality. To address this question, we conducted a population-based nested case–control study in Saskatchewan, Canada, where a population-based prescription drug database has existed since 1975. We evaluated fatal breast cancer risk in relation to recency and duration of use of CHT and unopposed estrogen hormone therapy (EHT). A total of 1,288 cases and 12,535 controls were included in the analyses. Exclusive use of EHT was not associated with fatal breast cancer risk, either overall or within categories of recency or duration [odds ratio (OR) for current vs. never use = 1.1; 95 % confidence interval (CI) 0.8–1.3]. Use of CHT (includes women who had also used EHT) was also not associated with fatal breast cancer risk (OR for current vs. never use = 0.9; 95 % CI 0.7–1.3), except for a suggestion of an increased risk with current long-term use. Consistent with prior studies, we observed no increased risk of fatal breast cancer associated with use of EHT. To date only a few studies have evaluated fatal breast cancer risk in relation to use of CHT, and collectively the results are inconsistent.
KeywordsBreast cancer Estrogen Progestin Mortality Menopause
We thank Dr. MaryRose Stang of the Saskatchewan Ministry of Health for assistance with data acquisition, and Barb Byrne Simon and Matthew Anderson of the University of Washington for administrative support. This Study is based in part on de-identified data provided by the Saskatchewan Ministry of Health. The interpretation and conclusions contained herein do not necessarily represent those of the Government of Saskatchewan or the Saskatchewan Ministry of Health.
Conflict of interest
The authors declare that they have no conflict of interest.
- 4.Chlebowski R, Hendrix S, Langer R, Stefanick M, Gass M, Lane D, Rodabough R, Gilligan M, Cyr M, Thomson C et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 289(24):3243–3253PubMedCrossRefGoogle Scholar
- 6.Chlebowski RT, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML, Lane DS, Johnson KC, Wactawski-Wende J, Chen C et al (2013) Estrogen plus progestin and breast cancer incidence and mortality in the Women’s Health Initiative Observational Study. J Natl Cancer Inst 105(8):526–535PubMedCentralPubMedCrossRefGoogle Scholar
- 7.Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, Gass M, Bluhm E, Connelly S, Hubbell FA, Lane D et al (2012) Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial. Lancet Oncol 13(5):476–486PubMedCentralPubMedCrossRefGoogle Scholar
- 8.Downey W, Strang M, Beck P, Osei W, Nichol JL (2005) Health services databases in Saskatchewan. In: Strom BL (ed) Pharmacoepidemiology, 4th edn. Wiley, Chichester, pp 295–310Google Scholar
- 9.World Health Organization (1977) Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death, 9th revision. WHO, GenevaGoogle Scholar
- 10.World Health Organization (1992) International Statistical Classification of Diseases and Related Health Problems, 10th revision. WHO, GenevaGoogle Scholar
- 12.Saskatchewan Cancer Agency. Screening Program for Breast Cancer. http://www.saskcancer.ca/Default.aspx?DN=80e4bb14-ed7d-4f79-852f-3316d42de414. Accessed 15 Oct 2012
- 13.Nichols HB, Visvanathan K, Newcomb PA, Hampton JM, Egan KM, Titus-Ernstoff L, Trentham-Dietz A (2011) Bilateral oophorectomy in relation to risk of postmenopausal breast cancer: confounding by nonmalignant indications for surgery? Am J Epidemiol 173(10):1111–1120PubMedCentralPubMedCrossRefGoogle Scholar
- 14.Press DJ, Sullivan-Halley J, Ursin G, Deapen D, McDonald JA, Strom BL, Norman SA, Simon MS, Marchbanks PA, Folger SG et al (2011) Breast cancer risk and ovariectomy, hysterectomy, and tubal sterilization in the women’s contraceptive and reproductive experiences study. Am J Epidemiol 173(1):38–47PubMedCentralPubMedCrossRefGoogle Scholar
- 15.Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, Johnson KC, Kuller LH, Lane DS, Wactawski-Wende J et al (2009) Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 170(1):12–23PubMedCentralPubMedCrossRefGoogle Scholar
- 17.McTiernan A, Martin C, Peck J, Aragaki A, Chlebowski R, Pisano E, Wang C, Brunner R, Johnson K, Manson J et al (2005) Estrogen-plus-progestin use and mammographic density in postmenopausal women: women’s health initiative randomized trial. J Natl Cancer Inst 97(18):1366–1376PubMedCrossRefGoogle Scholar
- 18.Chlebowski RT, Anderson G, Pettinger M, Lane D, Langer RD, Gilligan MA, Gillian MA, Walsh BW, Chen C, McTiernan A et al (2008) Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med 168(4):370–377; quiz 345Google Scholar
- 22.Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DS, Barlow WE, Cutter G, Geller BM, Yankaskas B, Taplin SH et al (2003) Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol 21(23):4314–4321PubMedCrossRefGoogle Scholar
- 27.International Agency for Research on Cancer (IARC) Working Group on the Evaluation of Carcinogenic Risk to Humans (2008: Lyon France) Combined estrogen–progestogen menopausal therapy. In: A review of human carcinogens Part A: pharmaceuticals, vol 100A. World Health Organization, Geneva, pp 249–282Google Scholar